$0.64
4.26% yesterday
NYSE, Sep 09, 10:15 pm CET
ISIN
US9286611077
Symbol
VNRX

VolitionRX Stock price

$0.64
+0.02 2.74% 1M
+0.06 9.83% 6M
+0.04 6.17% YTD
-0.03 4.63% 1Y
-1.12 63.70% 3Y
-2.55 80.03% 5Y
-3.86 85.84% 10Y
+0.24 59.25% 20Y
NYSE, Closing price Tue, Sep 09 2025
+0.03 4.26%
ISIN
US9286611077
Symbol
VNRX

Key metrics

Basic
Market capitalization
$68.5m
Enterprise Value
$73.2m
Net debt
$4.6m
Cash
$2.6m
Shares outstanding
100.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
52.3 | 14.8
EV/Sales
55.9 | 15.8
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-265.0%
Return on Equity
108.3%
ROCE
-9,664.9%
ROIC
-
Debt/Equity
-0.3
Financials (TTM | estimate)
Revenue
$1.3m | $4.6m
EBITDA
$-22.9m | $-15.7m
EBIT
$-24.2m | $-16.9m
Net Income
$-24.0m | $-18.8m
Free Cash Flow
$-22.4m
Growth (TTM | estimate)
Revenue
61.7% | 275.5%
EBITDA
32.6% | 39.0%
EBIT
31.6% | 37.4%
Net Income
31.2% | 30.1%
Free Cash Flow
-20.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,748.2% | -339.9%
EBIT
-1,846.7%
Net
-1,836.2% | -407.9%
Free Cash Flow
-1,707.9%
More
EPS
$-0.3
FCF per Share
$-0.2
Short interest
0.2%
Employees
85
Rev per Employee
$10.0k
Show more

Is VolitionRX a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

VolitionRX Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a VolitionRX forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a VolitionRX forecast:

Buy
82%
Hold
18%

Financial data from VolitionRX

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.31 1.31
62% 62%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
22% 22%
983%
- Research and Development Expense 11 11
38% 38%
863%
-23 -23
33% 33%
-1,746%
- Depreciation and Amortization 1.29 1.29
8% 8%
98%
EBIT (Operating Income) EBIT -24 -24
32% 32%
-1,844%
Net Profit -24 -24
31% 31%
-1,834%

In millions USD.

Don't miss a Thing! We will send you all news about VolitionRX directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

VolitionRX Stock News

Neutral
PRNewsWire
about 20 hours ago
HENDERSON, Nev. , Sept. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the signing of a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome ("APS") with Werfen's Immunoassay Technology Center, a worldwide leader in specialized diagnostics.
Neutral
Seeking Alpha
26 days ago
VolitionRx Limited (NYSE:VNRX ) Q2 2025 Earnings Conference Call August 15, 2025 8:30 AM ET Company Participants Andrew Retter - Chief Medical Officer Cameron Reynolds - Founder, CEO, President & Director Louise Batchelor Day - Group Chief Marketing & Communications Officer Terig Hughes - CFO & Treasurer Conference Call Participants Bruce David Jackson - The Benchmark Company, LLC, Research Div...
Neutral
PRNewsWire
27 days ago
Conference call to discuss financial and operational results scheduled for Friday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
More VolitionRX News

Company Profile

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Head office United States
CEO Cameron Reynolds
Employees 85
Founded 1998
Website volition.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today